|
[1] World Health Organization.Global health sector strategy on viral hepatitis 2016-2021[EB/OL]. (2016-06) [2018-03].http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/zh/.世界卫生组织.《2016-2021年全球卫生部门病毒性肝炎战略》[EB/OL]. (2016-06) [2018-03].http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/zh/
|
|
[2]CHANG TT, LIAW YF, WU SS, et al.Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B[J].Hepatology, 2010, 52 (3) :886-893.
|
|
[3]LOK AS.Hepatitis:long-term therapy of chronic hepatitis B reverses cirrhosis[J].Nat Rev Gastroenterol Hepatol, 2013, 10 (4) :199-200.
|
|
[4]MARCELLIN P, GANE E, BUTI M, et al.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:a 5-year open label follow up study[J].Lancet, 2013, 381 (9865) :468-475.
|
|
[5]WANG BQ, SUN YM, YOU H, et al.Pathological assessment of liver fibrosis regression[J].J Clin Hepatol, 2017, 33 (3) :435-437. (in Chinese) 王冰琼, 孙亚朦, 尤红, 等.肝纤维化逆转的病理评估[J].临床肝胆病杂志, 2017, 33 (3) :435-437.
|
|
[6]ZHOU JL, WEI W, YOU H.Progress in clinical studies of noninvasive early diagnosis of liver fibrosis and cirrhosis[J].J Clin Hepatol, 2014, 30 (7) :604-607. (in Chinese) 周家玲, 魏巍, 尤红.肝纤维化无创诊断技术的临床研究及进展[J].临床肝胆病杂志, 2014, 30 (7) :604-607.
|
|
[7]ZHANG X, XU Y, CHEN JM, et al.Huang Qi Decoction prevents BDL-induced liver fibrosis through inhibition of notch signaling activation[J].Am J Chin Med, 2017, 45 (1) :85-104.
|
|
[8]LIU S, WANG XM, YANG GW.Effect of RUANGANJIEDU decoction inhibit experimental hepatic fibrosis of rats[J].Afr J Tradit Complement Altern Med, 2017, 14 (1) :242-250.
|
|
[9]BAI GP, YAN GH, WANG GJ, et al.Anti-hepatic fibrosis effects of a novel turtle shell decoction by inhibiting hepatic stellate cell proliferation and blocking TGF-beta 1/Smad signaling pathway in rats[J].Oncol Rep, 2016, 36 (5) :2902-2910.
|
|
[10]LU W, GAO YH, WANG ZZ, et al.Effects of Anluohuaxianwan on transforming growth factor-beta1 and related signaling pathways in rats with carbon tetrachloride-induced liver fibrosis[J].Chin J Hepatol, 2017, 25 (4) :257-262. (in Chinese) 卢玮, 高玉华, 王珍子, 等.安络化纤丸对肝纤维化大鼠转化生长因子β1及相应信号通路的影响[J].中华肝脏病杂志, 2017, 25 (4) :257-262.
|
|
[11]XI SY, SHI MM, JIANG XQ, et al.The effects of Tao-Hong-Si-Wu on hepatic necroinflammatory activity and fibrosis in a murine model of chronic liver disease[J].J Ethnopharmacol, 2016, 180:28-36.
|
|
[12]ZHANG CZ, XIAO HM, SHI MJ, et al.Model of traditional Chinese medicine of chronic hepatitis B in the management of chronic disease[J].Chin J Integr Tradit West Med Liver Dis, 2016, 26 (3) :181-182, 184. (in Chinese) 张朝臻, 萧焕明, 施梅姐, 等.慢性乙型肝炎慢病管理中医模式初探[J].中西医结合肝病杂志, 2016, 26 (3) :181-182, 184.
|
|
[13]LIU LX.Evaluation of the TCM chronic disease management in community patients with chronic hepatitis B[D].Guangzhou:Guangzhou Univ Chin Med, 2017. (in Chinese) 刘乐鑫.中医特色慢病管理模式在社区慢性乙型病毒性肝炎中的效果评价[D].广州:广州中医药大学, 2017.
|
|
[14]WANG G, LI ZH, LI H, et al.Metabolic profile changes of CCl4-liver fibrosis and inhibitory effects of Jiaqi Ganxian granule[J].Molecules, 2016, 21 (6) :698.
|
|
[15]ZHANG HY, WANG XN, HU P, et al.Serum metabolomic characterization of liver fibrosis in rats and anti-fibrotic effects of YinChen-Hao-Tang[J].Molecules, 2016, 21 (1) :126.
|
DownLoad: